title: Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice.
abstract: Previously, we reported that minocycline, kanamycin and norfloxacin improved the survival rate in the E32511 model that we developed (FEMS Immunol Med Microbiol 26, 101-108, 1999), but fosfomycin did not. In this study, we investigated the effectiveness of azithromycin (AZM) against Stx2d-producing EHEC O91:H21 strain B2F1 or Stx2c-producing Escherichia coli strain E32511 treated with mitomycin C in vivo. Recently, we reported the effectiveness of AZM in our model and AZM strongly inhibited the release of Stx2c from E32511 in vitro (PLOS ONE e58959, 2013). However, it was very difficult to completely eliminate E32511 in the mouse feces by treatment with AZM alone. In this report, only AZM or Daio effectively promoted survival of mice infected with B2F1 compared to untreated mice. Furthermore, Daio inhibited the colonization of GFP-expressing B2F1 in the mouse intestine. Similarly, a combination of AZM and Daio in the E32511-infected mice reduced E32511 in the mouse feces and significantly improved survival.
authors.affiliation: Department of Bacteriology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Neurology, Hasanuddin University Teaching Hospital, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
authors.forename: Muhammad Yunus
authors.initials: MY
authors.lastname: Amran
authors.forename: Jun
authors.initials: J
authors.lastname: Fujii
authors.forename: Glynis L
authors.initials: GL
authors.lastname: Kolling
authors.forename: Sharon Y A M
authors.initials: SY
authors.lastname: Villanueva
authors.forename: Mosaburo
authors.initials: M
authors.lastname: Kainuma
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Hideko
authors.initials: H
authors.lastname: Kameyama
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Yoshida
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use*; D003106:Colon / Q000382:microbiology; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D019453:Escherichia coli O157 / Q000187:drug effects* / Q000472:pathogenicity; D005243:Feces / Q000382:microbiology; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000188:drug therapy*; D008516:Medicine, Chinese Traditional; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D016685:Mitomycin / Q000494:pharmacology; D022641:Shiga Toxin 2 / Q000378:metabolism; D054323:Shiga-Toxigenic Escherichia coli / Q000187:drug effects* / Q000472:pathogenicity
chemical_list: D000900:Anti-Bacterial Agents; D004365:Drugs, Chinese Herbal; D022641:Shiga Toxin 2; C087631:gou-teng; D016685:Mitomycin; D017963:Azithromycin
keywords: AZM; Daio; EHEC; Shiga toxin